Does SARS-CoV-2 infect the kidney? {#sec1}
==================================

The kidney seems to be a target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Su and colleagues examined the kidneys of patients who died of coronavirus 2019 (COVID-19), and using electron microscopy (EM), found spherical structures in podocytes and the tubular epithelium that were felt to be coronavirus inclusions. In addition, tubules stained for SARS-CoV-2 nucleoprotein were positive. Similarly, Kissling and colleagues reported collapsing focal segmental glomerular sclerosis (FSGS) in a patient with COVID-19 who experienced a rapid decline in kidney function. Spherical structures felt to be compatible with viral inclusions were seen in podocytes by EM, but reverse transcriptase polymerase chain reaction for SARS-CoV-2 RNA in the kidney was negative. Of note, 2 letters to the *Journal* pointed out that the EM structures described in these papers are more likely to be multivesicular bodies (MVB), and not coronavirus. The cover images compare (**a**) spherical particles with spikes in a podocyte of a COVID-19 patient, (**b**) a multivesicular body in a podocyte of a lupus patient, and (**c**) SARS-CoV-2 in tissue culture. The question of whether SARS-CoV-2 infects the kidney remains open. **See** **pages 219**, **228**, **231** **, and** **233**

Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets {#sec2}
==================================================================================================================================

Williams and colleagues used the *Col4a3* ^*--/--*^ (collagen IV/α3 chain deletion) model to identify drugs that could interfere with progression of kidney disease. This model develops abnormalities of the glomerular basement membrane (GBM), progressive interstitial fibrosis, and end-stage kidney disease. Transcript changes over time were identified by comparing young and aged mice. Based on differential transcript expression, a disease progression signature was developed and plugged into Connectivity Map (CMap). CMap is a tool that connects genes and existing drugs to identify compounds that can reverse a pathogenic transcript signature. CMap identified vorinostat, a lysine decatylase inhibitor, as the top hit for treating renal progression. Vorinostat reversed expression of a subset of the *Col4a3* ^*--/--*^ progression transcripts and modestly prolonged survival. Importantly, several of the *Col4a3* ^*--/--*^ progression genes were also found in human kidney diseases, such as FSGS. Animal modeling and analysis by CMap may facilitate drug repurposing to treat human kidney disease. **See** **page 116**

Long-term safety of kidney donation {#sec3}
===================================

To estimate the long-term risk of kidney donation, Kasiske and colleagues followed living kidney donors and controls prospectively for 9 years. Remarkably, over almost a decade of observation, kidney donors did not have more proteinuria or albuminuria than controls, and the measured glomerular filtration rate (GFR) of donors did not change much. In fact, GFR increased for the first 3 years postdonation, and then declined between years 3 and 9, but less so than controls. Similarly, Lam and colleagues conducted a retrospective study of estimated glomerular filtration rate (eGFR) in living donors over a decade and found that eGFR increased by over 1 ml/min per 1.73 m^2^ in the first 2 years after donation and 0.64 ml/min per 1.73 m^2^ between 2 and 5 years, and fell 0.06 ml/min per 1.73 m^2^ beyond 5 years. These data provide important reassurance that living kidney donation does not place donors at risk for future kidney disease. **See** **pages 168** **and** **176**

Positron emission tomography imaging of renal mitochondria is a powerful tool in the study of acute and progressive kidney disease models {#sec4}
=========================================================================================================================================

Mitochondrial dysfunction may have an important role in kidney disease, but this is hard to quantify *in vivo*. To examine mitochondria noninvasively, Saeki and colleagues developed a probe, ^18^F-BCPP-BF (BCPP), for positron emission tomography of the kidneys that specifically binds to mitochondrial complex I. This probe was used to image the kidneys in animal models of renal ischemia-reperfusion injury (I/R), 5/6 nephrectomy (5/6Nx), and anti-GBM glomerulonephritis (GN). After reperfusion in the I/R model, kidney uptake of BCPP was significantly reduced, and EM showed severe mitochondrial swelling in the S3 segment of the proximal tubule. In 5/6Nx animals, uptake of BCPP was reduced 15 weeks after surgery, but this was largely prevented by renin-angiotensin-aldosterone system (RAAS) blockade. In anti-GBM GN, uptake decreased progressively and declined as tubulointerstitial damage increased. The investigators concluded that BCPP imaging may be useful in defining the mass of healthy renal tubular cells. **See** **page 88**
